New physiological functions for drug-transporting P-glycoproteins?

Drug Resistance Updates

Volumn 1, Issue 5, 1998, Pages 337-339

  Borst, P ^a   van Blitterswijk, W J ^a   Borst, J ^a   Tepper, A D ^a   Schinkel, A H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000996317     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80049-6     Document Type: Note

References (40)

1. Higgins C.F. ABC transporters: From microorganisms to man. Annu Rev Cell Biol 8 (1992) 67-113
2. Randolph G.J., Beaulieu S., Pope M., et al. A physiologic function for p-glycoprotein (MDR-I) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc Natl Acad Sci USA 95 (1998) 6924-6929
3. Smyth M.J., Krasovskis E., Sutton V.R., and Johnstone R.W. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95 (1998) 7024-7029
4. Ruetz S., and Gros P. Functional expression of P-glycoproteins in secretory vesicles. J Biol Chem 269 (1994) 12277-12284
5. Rosenberg M.F., Callaghan R., Ford R.C., and Higgins C.F. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem 272 (1997) 10685-10694
6. Higgins C.F., Callaghan R., Linton K.J., et al. Structure of the multidrug resistance P-glycoprotein. Seminars in Cancer Biol 8 (1997) 135-142
7. Higgins C.F., and Gottesman M.M. Is the multidrug transporter a flippase?. Trends Biochem Sci 17 (1992) 18-21
8. Higgins C.F. Flip-Flop: The transmembrane translocation of lipids. Cell 79 (1994) 393-395
9. Bolhuis H., Van Veen H.W., Molenaar D., et al. Multidrug resistance in Lactococcus lactis: evidence for ATP-dependent drug extrusion from the inner leaflet of the cytoplasmic membrane. EMBO J 15 (1996) 4239-4245
10. Sandor V., Fojo T., and Bates S.E. Future perspectives for the development of P-glycoprotein modulators. Drug Resist Updates 3 (1998) 190-200
11. Sikic B.I. Pharmacologic approaches to reversing multidrug resistance. Seminars in Hematology 34 (1997) 40-47
12. Stein W.D. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiological Reviews 77 (1997) 545-590
13. Alahari S.K., Dean N.M., Fisher M.H., et al. Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol 50 (1996) 808-819
14. Peng Ho S., Britton D., Stone B.A., et al. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucl Acids Res 24 (1996) 1901-1907
15. Kobayashi H., Dorai T., Holland J.F., and Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDRI (PGYI) ribozyme. Cancer Res 54 (1994) 1271-1275
16. Matsushita H., Kizaki M., Kobayashi H., et al. Restoration of retinoid sensitivity by MDRI ribozymes in retinoic acid resistant myeloid leukemic cells. Blood 91 (1998) 2452-2458
17. Schinkel A.H., Smit J.J.M., Van Tellingen O., et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994) 491-502
18. Schinkel A.H., Mayer U., Wagenaar E., et al. Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94 (1997) 4028-4033
19. Branch A.D. A good antisense molecule is hard to find. TIBS 23 (1998) 45-50
20. Borst P., and Schinkel A.H. Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet 13 (1997) 217-222
21. Van Veen H.W., Venema K., Bolhuis H., et al. Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter MDRI. Proc Natl Acad Sci USA 93 (1996) 10668-10672
22. Van Veen H.W., Callaghan R., Soceneantu L., et al. A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene. Nature 391 (1998) 291-295
23. Hendrickson N., Sifri C.D., Henderson D.M., et al. Molecular characterization of the IdmdrI multidrug resistance gene from Leishmania donovani. Mol Biochem Parasitol 60 (1993) 53-64
24. Chow L.M.C., Wong A., Ullman B., and Wirth D. Cloning and functional analysis of an extrachromosomally amplified multidrug resistance-like gene in Leishmania enriettii. Mol Biochem Parasitol 60 (1993) 195-208
25. Gueiros-Filho F.J., Viola J.P.B., Gomes F., et al. Leishmania amazonensis: Multidrug resistance in vinblastine-resistant promastigotes is associated with rhodamine 123 efflux, DNA amplification, and RNA overexpression of a Leishmania mdrl gene. Exp Parasitol 81 (1995) 480-490
26. Chaudhary P.M., and Roninson I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66 (1991) 85-94
27. Klimecki W.T., Futscher B.W., Grogan T.M., and Dalton W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83 (1994) 2451-2458
28. Gupta S., and Aggarwal S. P-glycoprotein in cells of the human system. The Immunologist 4 (1996) 86-90
29. MacDonald H.R., Bommhardt U., and Cerottini J. Developmentally regulated expression of P-glycoprotein (multidrug resistance) activity in mouse thymocytes. Eur J Immunol 25 (1995) 1457-1460
30. Pilarski L.M., Paine D., McElhaney J.E., et al. Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during aging. Am J Hematol 49 (1995) 323-335
31. Weisburg J.H., Curcio M., Caron P.C., et al. The multidrug resistance phenotype confers immunological resistance. J Exp Med 183 (1996) 2699-2704
32. Chong A.-F., Markham P.N., Gebel H.M., et al. Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol Immunother 36 (1993) 133-139
33. Zalcberg J.R., Hu X.F., Wall D.M., et al. Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. Int J Cancer 57 (1994) 522-528
34. Landowski T.H., Gleason-Guzman M.C., and Dalton W.S. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 89 (1997) 1854-1861
35. Bezombes C., Maestre N., Laurent G., et al. Restoration of TNF--induced ceramide generation and apoptosis in resistant human leukemia KGIa cells by the P-glycoprotein blocker PSC833. FASEB J 12 (1998) 101-109
36. Bettaïeb A., Record M., Côme M.G., et al. Opposite effects of tumor necrosis factor alpha on the sphingomyelin-ceramide pathway in two myeloid leukemia cell lines: Role of transverse sphingomyelin distribution in the plasma membrane. Blood 88 (1996) 1465-1472
37. Tepper A.D., Boesen-de Cock J.G.R., DeVries E., et al. CD95/Fas-induced ceramide formation proceeds with slow kinetics and is not blocked by caspase-3/CPP32 inhibition. J Biol Chem 272 (1997) 24308-24312
38. van Helvoort A., Smith A.J., Sprong H., et al. MDRI P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87 (1996) 507-517
39. 6-NBD-sphingomyelin is translocated across the plasma membrane by a multidrug transporter activity. J Cell Sci 110 (1997) 75-83
40. Borst P. Editor's introduction. Seminars in Cancer Biol 8 (1997) 131-134